Systematic Case-Based Analysis of the Maurora® Drug-Eluting Stent in Vertebral Artery Intervention
DOI:
https://doi.org/10.62051/hvetyk14Keywords:
Vertebral artery; drug-eluting stent; in-stent restenosis.Abstract
Drug-eluting stent(DES) has reduced the rate of (ISR) and improved Vessel patency rate dramatically since it came out in 2002. However,the structure of vertebral artery is complex and has high rate of ISR, which causes a restriction of conventional bare-metal stent (BMS) and off-label coronary stents at this site. Maurora® sirolimus-eluting stent, as the first DES approved for vertebral artery indication all over the world, marked an important breakthrough in the field of neurointervention. This essay uses a systematic case-based approach to analyze the fluoropolymer coating design, drug-release mechanism, clinical performance, and practical challenges of the Maurora® stent. In a word, Maurora® deals with the challenges effectively in treating vertebral artery stenosis and provided a reference for the future optimization and development of DES in the neurovascular field, through the combined design of alloy material optimization, fluorinated coating, and drug-release system. Future direction may develop bioadaptive coatings and combination strategies to reduce restenosis and enhance neurovascular outcomes.
Downloads
References
[1] Wabnitz A, Chimowitz M. Angioplasty, stenting and other potential treatments of atherosclerotic stenosis of the intra- cranial arteries: past, present and future. J Stroke 2017;19: 271-276.
[2] WITYK R J, CHANG HM, ROSENGART A, et al. Proximal extracranial vertebral artery disease in the New England Medical Center Posterior Circulation Registry. Arch Neurol, 1998, 55(4): 470-478.
[3] Feng Yao, Li Long, Song Gang, et al. Literature review and status of extracranial vertebral artery stent implantation in China. Chinese Journal of Cerebrovascular Diseases, 2019, 16(6): 316-320.
[4] WANG Z, LING Y, ZHAO H, et al. A comparison of different endovascular treatment for vertebral artery origin stenosis World Neurosurg, 2022, 164: e1290-e1297.
[5] Stayman AN, Nogueira RG, Gupta R. A systematic review of stenting and angioplasty of symptomatic extracranial vertebral artery stenosis. Stroke, 2011, 42: 2212-2216.
[6] Tank VH, Ghosh R, Gupta V, et al. Drug eluting stents versus bare metal stents for the treatment of extracranial vertebral artery disease: a meta-analysis J Neurointerv Surg, 2016, 8: 770- 774.
[7] PUZ P, URBANEK T, ZIAJA D, et al. Factors associated with the symptomatic status of carotid artery stenosis: Identification in a cross-sectional study and development of a scoring system Pol Arch Intern Med, 2021, 131(1): 17-25.
[8] GIUSTINO G, COLOMBO A, CAMAJ A, et al. Coronary in- stent restenosis: JACC state-of-the-art review J Am Coll Cardiol, 2022, 80(4): 348-372.
[9] LEE S, ZHANG J, MINTZ GS, et al. Procedural characteristics of intravascular ultrasound -guided percutaneous coronary intervention and their clinical implications. J Am Heart Assoc, 2022, 11(14): e025258.
[10] SI JH, MA N, GAO F, et al. Effect of a drug-eluting stent vs. bare metal stent for the treatment of symptomatic intracranial and vertebral artery stenosis. Front Neurol, 2022, 13: 854226.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Environment, Energy and Earth Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
